Boundless Bio, Inc. (BOLD) Short-Term Debt to Capital

Boundless Bio, Inc. (BOLD) develops cancer treatments within US jurisdiction, which eliminates the impact of trade wars on medical innovation. Complex bioinformatic calculations and unique patents ensure a high barrier to entry. The share price retrospective for Boundless Bio, Inc. (BOLD) reflects dynamics based on the 0.00 metric. The business relies on the monopoly right to use extrachromosomal DNA technologies, guaranteeing high profitability over the long term.

This indicator calculates the ratio of liabilities with a maturity of up to one year relative to equity, allowing for an assessment of current financial stability and liquidity risks. An optimal borrowing balance is critically important for Boundless Bio, Inc. (BOLD), as it funds strict compliance with bioethical standards and the environmental safety of laboratories, which is reflected in the level of short-term debt to equity.